Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Alector Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
31Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05053035CT.gov A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Latozinemab (this asset) | Alector Inc. | P2 | CC · 46 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Riluzole | AB Science | P4 | BB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| mt-1186 | Tanabe Pharma Corporation | P3 | BB |
| Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors | Brainstorm-Cell Therapeutics | P3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Other indications for Latozinemab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Frontotemporal Dementia | — | P3 | B · 58 |
| Neurodegenerative Disease | — | P3 | CCC · 50 |
| Bipolar I Disorder | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Latozinemab in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/latozinemab-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →